Patents Assigned to University Court of the University of Aberdeen
-
Publication number: 20230256043Abstract: The present invention relates to the field of food technology and in particular, nutrient and bioactive rich plant formulations. Formulated products including nutrients and bioactives such as those provided by the Moringa plant are provided. In particular, coated or encapsulated food products having a spec release behaviour and a process for their production is described. The processes described enable food material, for example Moringa, to be used to provide nutrient dense foods that are more accessible and protected against loss of nutritional value. The resulting food products therefore allow better delivery of nutritional benefits to users.Type: ApplicationFiled: July 13, 2021Publication date: August 17, 2023Applicants: The University Court of the University of Aberdeen, Nutriigen Ltd.Inventors: Madalina NEACSU, Wendy Roslyn RUSSELL, Nigel Edmond YOUNG, Alan Michael ROWE, Victor THOMSON
-
Patent number: 11440880Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: GrantFiled: October 29, 2020Date of Patent: September 13, 2022Assignees: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Patent number: 11444427Abstract: A lasing device includes an active layer comprising a cholesteric liquid crystal material and a laser dye, and a liquid crystal cell including spaced apart substrates defining a cell gap in which the active layer is disposed. The substrates include electrodes arranged to bias the active layer into an oblique helicoidal (ChOH) state. At least one substrate of the liquid crystal cell is optically transparent for a lasing wavelength range of the device.Type: GrantFiled: November 15, 2016Date of Patent: September 13, 2022Assignees: Kent State University, The University Court of the University of AberdeenInventors: Jie Xiang, Andrii Varanytsia, Fred Minkowski, Oleg D. Lavrentovich, Peter Palffy-Muhoray, Corrie T. Imrie, Daniel E. Paterson, John M. Storey
-
Publication number: 20220257569Abstract: The present application pertains to methods of using indole-oxadiazole compounds of Formula I to modulate cannabinoid receptor activity: I In particular diseases, disorders or conditions that benefit from modulating cannabinoid receptor activity, such as non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), schizophrenia, bipolar disorder, psychosis, metabolic syndrome, type-2 diabetes, dyslipidaemia, obesity, eating disorders, cardiovascular diseases and disorders, and other conditions as described herein, may be treated. Also included in the present application are certain novel compounds of Formula Ia and pharmaceutical compositions comprising these compounds.Type: ApplicationFiled: September 12, 2019Publication date: August 18, 2022Applicants: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Iain Robert GREIG, Ruth ROSS, Amy RAMSEY, Catherine MIELNIK, Laurent Alain Claude TREMBLEAU, Mostafa Hamed ABDELRAHMAN
-
Publication number: 20220204595Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.Type: ApplicationFiled: March 15, 2022Publication date: June 30, 2022Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Neil Andrew Robert Gow, Fiona Marion Rudkin, Lars-Peter Erwig, Allan Jensen
-
Patent number: 11306138Abstract: This invention relates to recombinant human antibody molecules. The antibodies bind fungal antigens, for example from Candida spp. Human antibody encoding genes targeting clinically relevant Candida epitopes have been isolated from single B cells from carefully selected donors and screened with specified types of protein or cell wall extract. The panel of purified, fully human recombinant IgG1 mAbs generated displayed a diverse range of specific binding profiles and demonstrated efficacy in a disease model. The fully human mAbs and derivatives thereof have utility in the generation of diagnostics, therapeutics and vaccines.Type: GrantFiled: March 4, 2016Date of Patent: April 19, 2022Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Neil Andrew Robert Gow, Fiona Marion Rudkin, Lars-Peter Erwig, Allan Jensen
-
Publication number: 20210205462Abstract: The present disclosure relates to compositions comprising an SpHtp1 peptide translocation sequence and uses of such compositions. Also described are compositions comprising a payload coupled to an SpHtp1 peptide translocation sequence and their uses.Type: ApplicationFiled: May 29, 2019Publication date: July 8, 2021Applicant: The University Court of the University of AberdeenInventors: Franziska Trusch, Pieter Van West
-
Publication number: 20210047267Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: ApplicationFiled: October 29, 2020Publication date: February 18, 2021Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Patent number: 10865387Abstract: The present invention relates to methods of producing pancreatic endocrine cells and uses of the cells obtained using the methods. The method utilises inhibitors or combinations of factors to provide increased quantities of endocrine material, for example for transplantation purposes.Type: GrantFiled: May 14, 2015Date of Patent: December 15, 2020Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN REGENT WALKInventors: Kevin Docherty, Hilary Margaret Docherty, Maria Joao Marques De Lima, Kenneth Ross Muir, John Joseph Casey
-
Patent number: 10836721Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: GrantFiled: June 24, 2020Date of Patent: November 17, 2020Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Publication number: 20200325102Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: ApplicationFiled: June 24, 2020Publication date: October 15, 2020Applicants: The USA, as represented by the Secretary, Department of Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Patent number: 10730835Abstract: Thalidomide analogs and methods of using the thalidomide analogs are disclosed. Some embodiments of the disclosed compounds exhibit anti-angiogenic and/or anti-inflammatory activity. Certain embodiments of the disclosed compounds are non-teratogenic.Type: GrantFiled: September 29, 2016Date of Patent: August 4, 2020Assignees: The United States of America, as represented by the Secretary, Health and Human Services, University Court of the University of AberdeenInventors: Nigel H. Greig, Weiming Luo, David Tweedie, Neil Vargesson, Shaunna Beedie, William Douglas Figg
-
Patent number: 10647977Abstract: This invention relates to an engineered leader-independent heterocyclase (also known as a cyclodehydratase) comprising a defined cyanobactin leader sequence which drives the efficient conversion of heterocyclisable amino acids, such as Ser, Thr and Cys, within a peptide substrate lacking a leader sequence into heterocycles produce a homogenous heterocycle-containing product. This may be useful in biotechnology and chemical synthesis.Type: GrantFiled: November 4, 2015Date of Patent: May 12, 2020Assignees: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN, THE UNIVERSITY COURT OF THE UNIVERSITY OF ST. ANDREWSInventors: James Naismith, Jesko Koehnke, Andrew Bent, Nicholas Westwood, Greg Mann, Wael Houssen Ibrahim, Marcel Jaspars, Ying Ge
-
Patent number: 10532114Abstract: A synthetic calcium phosphate-based biomedical material comprising gadolinium. The material may comprises a compound having the general chemical formula: Ca10?yGdy(PO4)6?x(SiO4)x(OH)2?c+y where 0<x<1.3 and 0<y<1.3.Type: GrantFiled: January 27, 2017Date of Patent: January 14, 2020Assignees: ApaTech Limited, University Court of the University of AberdeenInventors: Iain Ronald Gibson, Janet Mabel Scott Skakle, Nigel Smith, Thomas Buckland
-
Publication number: 20200002403Abstract: The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules.Type: ApplicationFiled: February 11, 2019Publication date: January 2, 2020Applicant: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Caroline Jane BARELLE, William James Jonathan FINLAY, Alfredo DARMAN-IN-SHEEMAN, Andrew Justin Radcliffe PORTER
-
Patent number: 10472410Abstract: The present invention provides ICOSL specific antigen binding molecules which are isolated from immunized and synthetic Elasmobranchii derived libraries. In particular, the present invention relates to shark Variable New Antigen Receptor (VNAR) domains that specifically bind and neutralize the activity of human Induced Co-Stimulatory Ligand (ICOSL). The neutralizing VNAR domains are isolated from two independent sources; an immunized nurse shark library and a synthetic spiny dogfish framework fusion library. The molecules may be formulated as pharmaceutical compositions and used in medicine.Type: GrantFiled: April 23, 2014Date of Patent: November 12, 2019Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Caroline Jane Barelle, William James Jonathan Finlay, Alfredo Darmanin-Sheehan
-
Patent number: 10377711Abstract: The present disclosure relates to indole derivatives of the formula (I) which are cannabinoid type 1 receptor modulators and which are useful in the treatment of diseases in which modulation of the receptor is beneficial; to processes for their preparation; to pharmaceutical compositions comprising them; and to methods of using them.Type: GrantFiled: August 26, 2015Date of Patent: August 13, 2019Assignees: The University Court of the University of Aberdeen, The Governing Council of the University of TorontoInventors: Ruth Ross, Iain Greig, Matteo Zanda, Chih-Chung Tseng
-
Patent number: 10326143Abstract: An anode assembly for a fuel cell, the anode assembly having an anode catalyst component, said anode catalyst component comprising both a noble metal catalyst and a photo-catalyst, and said photo-catalyst being provided for enhancing contaminant carbon monoxide oxidation upon irradiation by incident radiation; the anode assembly further comprising a current collecting means electrically coupled to the anode catalyst component and being porous to said incident radiation and fuel for the fuel cell; and a flow plate incorporating a light source for providing incident radiation.Type: GrantFiled: October 22, 2010Date of Patent: June 18, 2019Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Angela Kruth, Malcolm John Todd, Donald Elliot Macphee, Richard Peter Kerwin Wells
-
Patent number: 10287341Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.Type: GrantFiled: September 22, 2016Date of Patent: May 14, 2019Assignee: The University Court of the University of AberdeenInventors: Caroline Barelle, Mischa Roland Muller, Valerie Calabro, Jack Bikker, John Steven, Lioudmila Tchistiakova, Oleg Kovalenko, Andrea Olland
-
Patent number: 10202438Abstract: The present invention provides methods for the production of a library of antigen specific antigen binding molecules having a peptide domain structure represented by the following formula (I): FW 1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 comprising (1) isolating RNA from a member of a species in the Elasmobranchii subclass; (2) amplifying DNA sequences from RNA obtained; (3) selecting a DNA sequence from the database prepared; (4) amplifying DNA sequences encoding two or more contiguous peptide domains of FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4; (5) ligating together said amplified DNA sequences to form DNA sequences encoding an antigen specific binding molecule; (6) cloning the amplified DNA obtained into a display vector; and (7) transforming a host with said display vector to produce a library of said antigen specific antigen binding molecules.Type: GrantFiled: April 23, 2014Date of Patent: February 12, 2019Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEENInventors: Caroline Jane Barelle, William James Jonathan Finlay, Alfredo Darman-In-Sheehan, Andrew Justin Radcliffe Porter